SG10201601301RA - Methods for predicting and improving the survival of gastric cancer patients - Google Patents

Methods for predicting and improving the survival of gastric cancer patients

Info

Publication number
SG10201601301RA
SG10201601301RA SG10201601301RA SG10201601301RA SG10201601301RA SG 10201601301R A SG10201601301R A SG 10201601301RA SG 10201601301R A SG10201601301R A SG 10201601301RA SG 10201601301R A SG10201601301R A SG 10201601301RA SG 10201601301R A SG10201601301R A SG 10201601301RA
Authority
SG
Singapore
Prior art keywords
predicting
survival
improving
methods
cancer patients
Prior art date
Application number
SG10201601301RA
Other languages
English (en)
Inventor
Phillip Kim
Sharat Singh
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of SG10201601301RA publication Critical patent/SG10201601301RA/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57446Specifically defined cancers of stomach or intestine
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/54Determining the risk of relapse
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/56Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SG10201601301RA 2011-04-04 2012-04-04 Methods for predicting and improving the survival of gastric cancer patients SG10201601301RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161471678P 2011-04-04 2011-04-04
US201261590787P 2012-01-25 2012-01-25

Publications (1)

Publication Number Publication Date
SG10201601301RA true SG10201601301RA (en) 2016-03-30

Family

ID=46000356

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2013071998A SG193626A1 (en) 2011-04-04 2012-04-04 Methods for predicting and improving the survival of gastric cancer patients
SG10201601301RA SG10201601301RA (en) 2011-04-04 2012-04-04 Methods for predicting and improving the survival of gastric cancer patients

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2013071998A SG193626A1 (en) 2011-04-04 2012-04-04 Methods for predicting and improving the survival of gastric cancer patients

Country Status (15)

Country Link
US (2) US20140099300A1 (es)
EP (1) EP2694972B8 (es)
JP (1) JP2014517259A (es)
KR (1) KR20140020318A (es)
CN (1) CN103597354B (es)
AU (1) AU2012240242A1 (es)
CA (1) CA2831468A1 (es)
DK (1) DK2694972T3 (es)
ES (1) ES2639650T3 (es)
IL (1) IL228579A0 (es)
MX (1) MX339340B (es)
NZ (1) NZ615738A (es)
RU (1) RU2013148768A (es)
SG (2) SG193626A1 (es)
WO (1) WO2012138785A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101327533B1 (ko) * 2012-12-11 2013-11-08 사회복지법인 삼성생명공익재단 환자 맞춤형 항암제 선별용 시스템
KR20160024639A (ko) 2014-08-26 2016-03-07 삼성전자주식회사 c-Met 표적 치료제의 저항성 또는 효능 예측을 위한 바이오마커 PDGF
CN105588943B (zh) * 2016-01-28 2018-03-02 山东省肿瘤防治研究院 一种胃癌患者外周血循环肿瘤细胞Her‑2基因的检测方法
CN105986034A (zh) * 2016-06-15 2016-10-05 南京卡迪睿伯生物技术有限公司 一组胃癌基因的应用
TWI639430B (zh) * 2016-08-27 2018-11-01 中國醫藥大學 醫藥組合物用於製備治療胃癌藥物的用途
WO2020092860A1 (en) * 2018-11-01 2020-05-07 The Jackson Laboratory Gastric cancer treatments
JP7493237B2 (ja) * 2018-11-14 2024-05-31 学校法人金沢医科大学 びまん性胃がんを治療するための医薬組成物
KR20220078117A (ko) 2020-12-03 2022-06-10 원광대학교산학협력단 혈액샘플을 이용한 코로나 환자 사망률 예측 시스템 및 방법
CN114594252A (zh) * 2020-12-03 2022-06-07 复旦大学附属中山医院 循环肿瘤细胞形态学特征在胃癌临床诊疗中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532138A (en) 1990-04-26 1996-07-02 Behringwerke Ag Method and kits for determining peroxidatively active catalysts
US5332662A (en) 1992-07-31 1994-07-26 Syntex (U.S.A.) Inc. Methods for determining peroxidatively active substances
DE69417242T2 (de) 1993-09-03 1999-07-08 Behringwerke Ag Fluoreszenz-sauerstoffkanalisation-immunteste
JP5154557B2 (ja) 2006-09-21 2013-02-27 ネステク ソシエテ アノニム 希少循環細胞における多様なシグナル伝達物質検出のための抗体に基づくアレイ
BRPI0717416A2 (pt) * 2006-09-21 2013-11-12 Prometheus Lab Inc Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo
ES2526211T3 (es) 2007-07-13 2015-01-08 Nestec S.A. Selección de fármacos para la terapia del cáncer de pulmón utilizando matrices basadas en anticuerpos
CN102016581B (zh) 2008-02-25 2014-07-30 雀巢产品技术援助有限公司 用抗体阵列选择乳腺癌治疗药物
CN102361883A (zh) * 2009-04-07 2012-02-22 罗氏格黎卡特股份公司 双特异性抗-ErbB-1/抗-c-Met抗体
WO2010132723A1 (en) 2009-05-14 2010-11-18 Prometheus Laboratories Inc. Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
JP5795311B2 (ja) * 2009-07-15 2015-10-14 ネステク ソシエテ アノニム 抗体ベースのアレイを使用する胃癌療法のための薬物選択
KR20120110168A (ko) 2009-10-20 2012-10-09 프로메테우스 레버러터리스 인코포레이티드 종양원성 융합 단백질을 검출하기 위한 근접-매개 검정법
JPWO2011125458A1 (ja) * 2010-04-02 2013-07-08 富士レビオ株式会社 抗癌剤の効果の診断用マーカー

Also Published As

Publication number Publication date
RU2013148768A (ru) 2015-05-10
CN103597354B (zh) 2016-04-20
AU2012240242A1 (en) 2013-10-10
SG193626A1 (en) 2013-10-30
JP2014517259A (ja) 2014-07-17
ES2639650T3 (es) 2017-10-27
WO2012138785A1 (en) 2012-10-11
EP2694972B8 (en) 2017-08-16
US20140099300A1 (en) 2014-04-10
NZ615738A (en) 2015-11-27
IL228579A0 (en) 2013-12-31
CA2831468A1 (en) 2012-10-11
MX339340B (es) 2016-05-20
KR20140020318A (ko) 2014-02-18
CN103597354A (zh) 2014-02-19
DK2694972T3 (en) 2017-10-02
EP2694972A1 (en) 2014-02-12
US20170285044A1 (en) 2017-10-05
MX2013011431A (es) 2014-06-06
EP2694972B1 (en) 2017-06-21

Similar Documents

Publication Publication Date Title
HK1254859A1 (zh) 治療乳腺癌的方法
HK1199099A1 (en) Methods and compositions for the treatment and diagnosis of cancer
HK1199100A1 (en) Methods and compositions for the treatment and diagnosis of colorectal cancer
SI2619576T1 (sl) Sredstva in metode za predvidevanje odziva rakavega pacienta na zdravljenje
IL228738A0 (en) Antibodies for cancer treatment
ZA201308111B (en) Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
HK1203091A1 (en) Methods for diagnosis of lung cancer
IL228579A0 (en) Methods for predicting and improving the survival of gastric cancer patients
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
EP2688594A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP2723924A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF CANCER
SG2014014724A (en) METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS
EP2651443A4 (en) ANTI-CCL25 AND ANTI-CCR9 ANTIBODIES FOR THE PREVENTION AND TREATMENT OF CANCER AND THE MIGRATION OF CANCER CELLS
EP2700652A4 (en) DIAGNOSIS AND TREATMENT OF CANCER BY ANTI-ITM2A ANTIBODIES
HK1185874A1 (zh) 用於治療癌症的新的 -氨基- -羥基-苯甲酰胺
IL228430A0 (en) Cancer treatment
SG11201402115TA (en) Methods for diagnosis and/or prognosis of gynecological cancer
IL275636A (en) Medical combination for cancer treatment
EP2635121A4 (en) ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER
EP2750508A4 (en) COMPOUNDS AND THERAPEUTIC METHODS
EP2710379A4 (en) METHODS OF DETERMINING THE PROBABILITY OF SURVIVAL AND EVALUATION OF THE PROBABILITY OF METASTASES IN CANCER PATIENTS
PL2746404T3 (pl) Środek przeciwnowotworowy i sposób przewidywania efektu terapeutycznego u pacjentów z rakiem jelita grubego z mutacją kras
EP2849786A4 (en) METHOD FOR THE TREATMENT OF GASCULAR CANCER
EP2709730A4 (en) TREATMENT AND PROGNOSIS OF CANCER
HK1213584A1 (zh) 用於治療癌症的 抗體及方法